Survivin in brain tumors: an attractive target for immunotherapy
- 1 August 2003
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 64 (1-2) , 71-76
- https://doi.org/10.1007/bf02700022
Abstract
Survivin, a member of the inhibitor of apoptosis proteins gene family, was recently shown to be expressed by tumors originating from different cell lineages. There are also cumulative evidences that spontaneous immune response against survivin derived epitopes may occur. Here, using RT-PCR, Western-blot analysis and immunohistochemistry, we show that survivin is widely expressed by gliomas, meningiomas and schwannomas, both in vitro and in vivo. These data indicate that survivin may serve as an attractive target for immunotherapies designed for brain tumors.Keywords
This publication has 23 references indexed in Scilit:
- Quantitatively Determined Survivin Expression Levels Are of Prognostic Value in Human GliomasJournal of Clinical Oncology, 2002
- Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34+ cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesisBlood, 2001
- Heightened expression of survivin in activated T lymphocytes from patients with multiple sclerosisJournal of Neuroimmunology, 2001
- Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.2001
- Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumorsCancer, 2001
- Neuroendocrine cells in human prostate over‐express the anti‐apoptosis protein survivinThe Prostate, 2001
- Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients.2001
- Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides.2000
- Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?Journal of Clinical Investigation, 1997